Standard BioTools Inc. (LAB)
LAB Stock Price Chart
Explore Standard BioTools Inc. interactive price chart. Choose custom timeframes to analyze LAB price movements and trends.
LAB Company Profile
Discover essential business fundamentals and corporate details for Standard BioTools Inc. (LAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Equipment & Services
IPO Date
10 Feb 2011
Employees
388.00
Website
https://www.standardbio.comCEO
Michael Egholm
Description
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
LAB Financial Timeline
Browse a chronological timeline of Standard BioTools Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $20.80m.
Earnings released on 5 May 2026
EPS came in at -$0.02 matching the estimated -$0.02, while revenue for the quarter reached $21.15m , beating expectations by +18.80%.
Earnings released on 24 Feb 2026
EPS came in at $0.06 surpassing the estimated -$0.03 by +300.00%, while revenue for the quarter reached $23.80m , beating expectations by +28.61%.
Earnings released on 4 Nov 2025
EPS came in at -$0.04 falling short of the estimated -$0.03 by -60.00%, while revenue for the quarter reached $19.55m , beating expectations by +5.69%.
Earnings released on 11 Aug 2025
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $21.76m , missing expectations by -46.75%.
Earnings released on 6 May 2025
EPS came in at -$0.04 matching the estimated -$0.04, while revenue for the quarter reached $40.80m , beating expectations by +3.98%.
Earnings released on 26 Feb 2025
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $46.72m , beating expectations by +8.56%.
Earnings released on 30 Oct 2024
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%, while revenue for the quarter reached $44.97m , beating expectations by +4.50%.
Earnings released on 31 Jul 2024
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $37.21m , missing expectations by -9.92%.
Earnings released on 8 May 2024
EPS came in at -$0.23 falling short of the estimated -$0.09 by -155.56%, while revenue for the quarter reached $45.54m , missing expectations by -1.01%.
Earnings released on 28 Feb 2024
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $28.19m , beating expectations by +13.20%.
Earnings released on 7 Nov 2023
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $25.37m , beating expectations by +7.49%.
Earnings released on 8 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.21 by +33.33%, while revenue for the quarter reached $27.67m , beating expectations by +14.32%.
Earnings released on 9 May 2023
EPS came in at -$0.11 falling short of the estimated -$0.06 by -98.77%, while revenue for the quarter reached $25.12m , missing expectations by -11.43%.
Earnings released on 14 Feb 2023
EPS came in at -$0.19 falling short of the estimated -$0.11 by -72.73%, while revenue for the quarter reached $27.02m , missing expectations by -28.89%.
Earnings released on 8 Nov 2022
EPS came in at -$0.26 falling short of the estimated -$0.13 by -100.00%, while revenue for the quarter reached $25.65m , missing expectations by -17.14%.
Earnings released on 8 Aug 2022
EPS came in at -$0.33 falling short of the estimated -$0.13 by -153.85%, while revenue for the quarter reached $18.78m , missing expectations by -36.95%.
Earnings released on 5 May 2022
EPS came in at -$0.25 falling short of the estimated -$0.15 by -66.67%, while revenue for the quarter reached $26.50m , beating expectations by +3.33%.
Earnings released on 17 Feb 2022
EPS came in at -$0.12 surpassing the estimated -$0.28 by +57.14%, while revenue for the quarter reached $38.27m , beating expectations by +17.11%.
Earnings released on 8 Nov 2021
EPS came in at -$0.18 surpassing the estimated -$0.22 by +18.18%, while revenue for the quarter reached $28.50m .
Earnings released on 5 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.19 by -21.05%, while revenue for the quarter reached $31.02m .
LAB Stock Performance
Access detailed LAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
